The Biological Basis of Bulimia

  • Peter M. Bolo


It is widely held that the etiology of bulimia nervosa involves a complex interplay of biological, psychological, and sociological factors. This is reflected in the wide range of treatment strategies now employed for this illness. Bulimia fits a biopsychosocial model of psychiatric illness well.


Eating Disorder Bulimia Nervosa Opiate Antagonist Ventromedial Hypothalamus Bulimic Symptom 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Leibowitz SF. Brain neurotransmitters and drug effects on food intake and appetite: Implications for eating disorders. In Walsh BT (ed): Eating Behavior in Eating Disorders. Washington, DC, American Psychiatric Press, 1988; 21–35.Google Scholar
  2. 2.
    Morley JE, Levine AS. The central control of appetite. Lancet 1983; 1: 398–401.PubMedCrossRefGoogle Scholar
  3. 3.
    Levy AB, Dixon KN, Stern SL. How are depression and bulimia related? Am J Psychiatry 1989; 146: 162–169.PubMedGoogle Scholar
  4. 4.
    Hudson JI, Pope HG, Jonas JM. Phenomenologic relationship of eating disorders to major affective disorder. Psychiatry Res 1983; 9: 345–354.PubMedCrossRefGoogle Scholar
  5. 5.
    Walsh BT, Roose SP, Glassman AH. Bulimia and depression. Psychosom Med 1985; 47: 123–131.PubMedGoogle Scholar
  6. 6.
    Pyle RL, Mitchell JE, Eckert ED. Bulimia: A report of 34 cases. J Clin Psychiatry 1981; 42: 60–64.PubMedGoogle Scholar
  7. 7.
    Lee NF, Rush AJ, Mitchell JE. Bulimia and depression. J Affective Disord 1985; 9: 231–238.CrossRefGoogle Scholar
  8. 8.
    Musisi S, Garfinkel P. Comparative dexamethasone suppression test measurements in bulimia, depression and normal controls. Can J Psychiatry 1985; 30: 190–194.PubMedGoogle Scholar
  9. 9.
    Stern SL, Dixon KN, Nemzer E. Affective disorder in the families of women with normal weight bulimia. Am J Psychiatry 1984; 141: 1224–1227.PubMedGoogle Scholar
  10. 10.
    Katz JL, Kuperberg A, Pollock CP. Is there a relationship between eating disorder and affective disorder? New evidence from sleep recordings. Am J Psychiatry 1984; 141: 753–759.PubMedGoogle Scholar
  11. 11.
    Levy AB, Dixon KN, Schmidt H. Sleep architecture in anorexia nervosa and bulimia. Biol Psychiatry 1988; 23: 99–101.PubMedCrossRefGoogle Scholar
  12. 12.
    Pope HG, Hudson JI, Jonas JM, Yurgelon-Todd D. Bulimia treated with imipramine: A placebo-controlled double-blind study. Am J Psychiatry 1983; 140: 554–558.PubMedGoogle Scholar
  13. 13.
    Pope HG, Hudson JI, Jonas JM, Yurgelon-Todd D. Antidepressant treatment of bulimia: A two-year follow-up study. J Clin Psychopharmacol 1985; 5: 320–327.PubMedGoogle Scholar
  14. 14.
    Agras WS, Dorian B, Kirkley BG, Arnow B, Bachman J. Imipramine in the treatment of bulimia: A double-blind controlled study. Mt J Eating Disord 1987; 6: 29–38.CrossRefGoogle Scholar
  15. 15.
    Mitchell JE, Groat R. A placebo-controlled, double-blind trial of amitriptyline in bulimia, J Clin Psychopharmacol 1984; 4: 186–193.PubMedCrossRefGoogle Scholar
  16. 16.
    Hughes PL, Wells LA, Cunningham CJ, Ilstrup DM. Treating bulimia with desipramine: A double-blind, placebo-controlled study. Arch Gen Psychiatry 1986; 43: 182–186.PubMedGoogle Scholar
  17. 17.
    Barlow J, Blouin J, Blouin A, Perez E. Treatment of bulimia with desipramine: A double-blind crossover study. Can J Psychiatry 1988; 33: 129–133.PubMedGoogle Scholar
  18. 18.
    Blouin J, Blouin A, Perez E, Barlow J. Bulimia: Independence of antibulimic and antidepressant properties of desipramine. Can J Psychiatry 1989; 34: 24–39.PubMedGoogle Scholar
  19. 19.
    Sabine EJ, Yonace A, Farrington AJ, Barratt KH, Wakeling A. Bulimia nervosa: A placebo-controlled double-blind therapeutic trial of mianserin. Br J Clin Pharmacol 1983; 15: 195S–202S.PubMedGoogle Scholar
  20. 20.
    Pope HG, Hudson JI. Antidepressant drug therapy for bulimia: Current status. J Clin Psychiatry 1986; 47: 339–345.PubMedGoogle Scholar
  21. 21.
    McGrath PJ, Quitkin FM, Stewart JW. An open trial of mianserin. Am J Psychiatry 1981; 138: 530–532.PubMedGoogle Scholar
  22. 22.
    Walsh BT, Gladis M, Roose SP, Stewart JW, Stetner F, Glassman A. Phenelzine vs placebo in 50 patients with bulimia. Arch Gen Psychiatry 1988; 45: 471–475.PubMedGoogle Scholar
  23. 23.
    Kennedy SH, Piran N, Warsh JJ, Prendergast P, Mainprize E, Whynot C, Garfinkel PE. A trial of isocarboxazid in the treatment of bulimia nervosa. J Clin Psychopharmacol 1988; 8: 391–396.PubMedCrossRefGoogle Scholar
  24. 24.
    Pope HG, Keck PE, McElroy SL, Hudson JI. A placebo-controlled study of trazodone in bulimia nervosa. J Clin Psychopharmacol 1989; 9: 254–259.PubMedCrossRefGoogle Scholar
  25. 25.
    Hsu LKG. Treatment of bulimia with lithium. Am J Psychiatry 1984; 141: 1260–1262.PubMedGoogle Scholar
  26. 26.
    Hsu LKG, Clement L, Santhouse R. Treatment of bulimia with lithium: A preliminary study. Psychopharmacol Bull 1987; 23: 45–48.PubMedGoogle Scholar
  27. 27.
    Pope HG, Herridge PL, Hudson JI, Fontaine R, Yurgelon-Todd D. Treatment of bulimia with nomifensine. Am J Psychiatry 1986; 143: 371–373.PubMedGoogle Scholar
  28. 28.
    Home RL, Ferguson JM, Pope HG, Hudson JI, Lineberry CG, Ascher J, Cato A. Treatment of bulimia with bupropion: A multicenter controlled trial. J Clin Psychiatry 1988; 49: 262–266.Google Scholar
  29. 29.
    Green RS, Rau JH. Treatment of compulsive eating disturbances with anti-convulsant medication. Am J Psychiatry 1974; 131: 428–432.PubMedGoogle Scholar
  30. 30.
    Rau JH, Green RS. Compulsive eating: A neuropsychologic approach to certain eating disorders. Comp Psychiatry 1975; 16: 223–231.CrossRefGoogle Scholar
  31. 31.
    Wermuth BM, Davis KL, Hollister LE, Stunkard AJ. Phenytoin treatment of the binge-eating syndrome. Am J Psychiatry 1977; 134: 1249–1253.PubMedGoogle Scholar
  32. 32.
    Kaplan AS. Anticonvulsant treatment of eating disorders. In Garfinkel PE, Garner DM (eds): The Role of Drug Treatments for Eating Disorders. New York, Brunner/Mazel, 1987; 96–123.Google Scholar
  33. 33.
    Rau JH, Green RS. Binge-purge syndrome. Neurological factors affecting binge eating: Body over mind. In Hawkins RG, Fremouw WJ, Clement PF (eds): Diagnosis, Treatment and Research. New York, Springer, 1984; 123–143.Google Scholar
  34. 34.
    Wegner JR, Struve FA. Incidence of the 14- and 6-per-second positive spike pattern in an adult clinical population: An empirical note. J Nery Ment Dis 1977; 164: 340–345.CrossRefGoogle Scholar
  35. 35.
    Kaplan AS, Garfinkel PE, Darby PL, Garner DM. Carbamazepine in the treatment of bulimia. Am J Psychiatry 1983; 140: 1225–1226.PubMedGoogle Scholar
  36. 36.
    Herridge PL, Pope HG. Treatment of bulimia and rapid-cycling bipolar disorder with sodium valproate: A case report. J Clin Psychopharmacol 1985; 5: 229–230.PubMedCrossRefGoogle Scholar
  37. 37.
    Morley JE, Levine AS, Grace M. An investigation of the role of kappa opiate receptor agonists in the initiation of feeding. Life Sci 1982; 31: 2617–2626.PubMedCrossRefGoogle Scholar
  38. 38.
    Mitchell JE, Morley JE. Endogenous opioid peptides and feeding. In Hudson JI, Pope HG (eds): The Psychobiology of Bulimia. Washington, DC, American Psychiatric Press, 1987; 101–113.Google Scholar
  39. 39.
    Mitchell JE, Laine DE, Morley JE, Levine AS. Naloxone but not CCK-8 may attenuate binge-eating behavior in patients in with the bulimia syndrome. Biol Psychiatry 1987, 21: 1399–1406.CrossRefGoogle Scholar
  40. 40.
    Jonas JM, Gold MS. Opiate antagonists as clinical probes in bulimia. In Hudson JI, Pope HG (eds): The Psychobiology of Bulimia. Washington, DC, American Psychiatric Press, 1987; 117–127.Google Scholar
  41. 41.
    Jonas JM, Gold MS. The use of opiate antagonists in treating bulimia: A study of low-dose versus high-dose naltrexone. Psychiatry Res 1988; 24: 195–199.PubMedCrossRefGoogle Scholar
  42. 42.
    Mitchell JE, Christenson G, Jennings J, Huber M, Thomas B, Pomeroy C, Morley J. A placebo-controlled, double-blind crossover study of naltrexone hydrochloride in outpatients with normal weight bulimia. J Clin Psychopharmacol 1989; 9: 94–97.PubMedCrossRefGoogle Scholar
  43. 43.
    Goldbloom DS. Serotonin in eating disorders: Theory and therapy. In Garfinkel PE, Garner DM (eds): The Role of Drug Treatments for Eating Disorders. New York, Brunner/Mazel, 1987; 124–149.Google Scholar
  44. 44.
    Kaye WH, Ebert MH, Gwirtsman HE, Weiss SR. Differences in brain serotonergic metabolism between nonbulimic and bulimic patients with anorexia nervosa. Am J Psychiatry 1984; 141: 1159–1161.Google Scholar
  45. 45.
    Robinson PH, Checkley SA, Russell GFM. Suppression of eating by fenfluramine in patients with bulimia nervosa. Br J Psychiatry 1985; 146: 169176.Google Scholar
  46. 46.
    Ong YL, Checkley SA, Russell GFM. Suppression of bulimic symptoms with methylamphetamine. Br J Psychiatry 1983; 1143: 288–293.CrossRefGoogle Scholar
  47. 47.
    Blouin AG, Blouin JH, Perez EL, Bushnik T, Zuro C, Mulder E. Treatment of bulimia with fenfluramine and desipramine. J Clin Psychopharmacol 1988; 8261–8269.Google Scholar
  48. 48.
    Russell GFM, Checkley SA, Feldman J, Eisler I. A controlled trial of dfenfluramine in bulimia nervosa. Clin Neuropharmacol 1988; 11: S149–S159.Google Scholar
  49. 49.
    Fuller RW, Perry KW, Molloy BB. Effect of an uptake inhibitor of serotonin metabolism in rat brain. Life Sci 1974; 15: 1161–1171.PubMedCrossRefGoogle Scholar
  50. 50.
    Ferguson JM. Fluoxetine-induced weight loss in overweight, non-depressed subjects. Am J Psychiatry 1986; 143: 1496.Google Scholar
  51. 51.
    Enas GG, Pope HG, Vevine LR. Fluoxetine in bulimia nervosa: A double-blind study [abstr]. Presented at the American Psychiatric Association. San Francisco, May 11, 1989.Google Scholar
  52. 52.
    Foss I, Trygstad O, Jettestad S. Double-blind study of fluoxetine and placebo in treatment of bulimia nervosa [abstr]. Presented at the Fourth International Conference on Eating Disorders. New York, April 28, 1990.Google Scholar
  53. 53.
    Freeman CP, Morris JE, Cheshire KE. A double-blind controlled trial of fluoxetine versus placebo for bulimia nervosa [abstr]. Presented at the Second International Conference On Eating Disorders. New York, April 22–24, 1988.Google Scholar

Copyright information

© Springer-Verlag New York Inc. 1993

Authors and Affiliations

  • Peter M. Bolo

There are no affiliations available

Personalised recommendations